期刊文献+

1例肺曲霉病患者抗真菌治疗中伏立康唑给药间隔和给药剂量分析 被引量:3

Exploration of the administration interval and dosage of voriconazole in antifungal treatment of a patient with pulmonary aspergillosis
原文传递
导出
摘要 目的分析伏立康唑给药间隔对其疗效和不良反应的影响,以及患者体质量与给药剂量之间的关系。方法通过对1例肺曲霉菌病患者在抗真菌治疗过程中伏立康唑给药间隔和给药剂量调整的分析及药学监护,探讨伏立康唑bid、q12h给药间隔与临床疗效和不良反应的关系,以及超重患者剂量调整的依据。结果伏立康唑依据AUC/MIC评价临床疗效,不受给药间隔影响,但bid给药可引起血药浓度波动,会增加不良反应发生的风险;超重患者按照实际体质量换算给药剂量,剂量偏高,可能导致血药浓度过高,不良反应增加。结论伏立康唑最佳给药间隔为q12h,超重患者按照校正体质量换算给药剂量,取得了满意的治疗效果并避免不良反应的发生。
作者 史文秀 叶晓芬 蔡映云 吕迁洲 SHI Wenxiu;YE Xiaofen;CAI Yingyun
出处 《中国临床药学杂志》 CAS 2020年第3期223-226,共4页 Chinese Journal of Clinical Pharmacy
  • 相关文献

参考文献4

二级参考文献59

  • 1黄成坷,邱相君,胡国新,代宗顺.伏立康唑分散片人体生物等效性研究[J].中国药学杂志,2007,42(16):1241-1243. 被引量:13
  • 2Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenousto oral-dose escalation regimens[J]. Antimicrob A- gents Chemother ,2002 ,46( 8) :2546-2553.
  • 3Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients[J] . Antimicrob Agents Chemother,2010,54(10) :4424-4431.
  • 4Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections[J]. Clin Infect Dis, 2012 , 55 ( 3 ) : 381-390.
  • 5Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent[J]. BrJ Clin Pharmacol,2003,56(Suppll) :2-9.
  • 6Purkins L, Wood N , Greenhalgh K, et al. V oriconazole , a novel wide-spectrum trizole , oral pharmacokinetics and safety[J]. BrJ Clin Pharmacol, 2003 ,56 ( Suppl 1) : 10-16.
  • 7Purkins L, Wood N, Kleinermans D, et al. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voricon- azole[J] . BrJ Clin Pharmacol, 2003 , 56 (Suppl 1) : 51-55.
  • 8Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole[J]. BrJ Clin Pharmacol,2003,56(Suppll) :56-6l.
  • 9Purkins L, Wood N , Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole[J]. BrJ Clin Pharmacol, 2003 , 56 (Suppl 1): 17-23.
  • 10Williams D. The effect of enteral nutrition supplements on serum voriconazole levels[J] .J Oncol Pharm Pract, 2012,18(1) : 128-13l.

共引文献82

同被引文献36

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部